Neumora Therapeutics
Pioneering a new era of precision medicines for brain diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
* | N/A | $305m | IPO |
| Total Funding | 000k | ||
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2026 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Neumora Therapeutics is pioneering the development of precision medicines for brain diseases, addressing the unmet needs in neuropsychiatric and neurodegenerative disorders. The company operates in the biopharmaceutical sector, focusing on Central Nervous System (CNS) diseases. Neumora's business model revolves around leveraging its proprietary Precision Toolbox, which integrates translational, clinical, and computational tools to develop targeted treatments. This approach aims to revolutionize the treatment landscape by focusing on novel mechanisms of action, rather than traditional drug classes. Neumora serves patients suffering from brain diseases, a market that affects over 1.5 billion people globally. The company generates revenue through the development and commercialization of its innovative drug pipeline, which is designed to offer more effective and targeted treatment options.
Keywords: precision medicine, CNS diseases, neuropsychiatric, neurodegenerative, pharmacology, translational tools, clinical tools, computational tools, drug development, brain diseases.